Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Viral Genetics Responds To Rumors Of Imminent FDA Filing
Viral Genetics has issued this announcement in response to a series of press releases distributed by collegestock.com on August 25 and August 26, and an article published on
Viral Genetics has issued this announcement in response to a series of press releases distributed by collegestock.com on August 25 and August 26, and an article published on
Piramal Life Sciences has completed the phase-I clinical trials of a new drug for the treatment of diabetes – reported IANS. The company said in a statement that
Resverlogix has released several quarterly updates for RVX-208, as apotential treatment of atherosclerosis and cardiovascular disease. The company claims that the phase 1b/2a study testing RVX-208 for 28
Cadila Pharmaceuticals has introduced 5-in-1 wonder pill – Polycap in the domestic market, reported Times of India. The new pill is expected to be a combination of five
Medicago has received clearance from Health Canada to commence a phase I human clinical trial with its H5N1 Avian Influenza vaccine. Enrollment of volunteers is currently underway. According
DATATRAK has signed two new studies with a global research-based biopharmaceutical company, which includes a multi-site, five-year study. The company said that the contract demonstrates a long-term commitment
The FDA has accepted Labopharm’s response regarding its novel formulation of the antidepressant – trazodone as complete, and designated it as a Class 2 resubmission. Labopharm has received
Protalix has received Fast Track Designation from the FDA for prGCD, the company’s proprietary plant-cell expressed recombinant form of glucocerebrosidase (GCD). It is intended for the treatment of
CardioDx, a cardiovascular genomic diagnostics company, has completed its multicenter validation study for Corus CAD. It is a gene expression test to quantify the likelihood of obstructive coronary
Nanosphere has submitted a 510(k) application to the FDA for its influenza and respiratory syncytial virus (RSV) test to run on the Verigene SP, with complete sample-to-result automation.